Rare Genetic Disease
Esteve Pharmaceuticals S.A. is engaged in clinical research for mucopolysaccharidosis type IIIA, also known as Sanfilippo A syndrome, a rare inherited lysosomal storage disorder affecting the central nervous system and childhood development.
- Mucopolysaccharidosis type IIIA
- Sanfilippo A syndrome
- Lysosomal storage disorder
The sponsor’s research interest is centered on neurological manifestations linked to this metabolic disease, with attention to conditions that involve progressive neurodegeneration and developmental impairment.
Gene-Based Neurological Therapy
The funded research focuses on gene therapy for a paediatric neurogenetic condition, using a viral vector approach designed to deliver the human sulfamidase gene to the brain.
- Gene therapy
- Adeno-associated viral vector
- Sulfamidase
This area reflects interest in restoring deficient enzyme activity in disorders caused by inherited metabolic defects affecting neural tissue.
Intracerebral Delivery
Clinical research activity includes intracerebroventricular administration, a route used to target therapeutic delivery directly to the central nervous system in order to address disease burden within the brain and spinal fluid spaces.
- Intracerebroventricular administration
- Central nervous system targeting
- Brain-directed treatment
The therapeutic emphasis is on neurological access for inherited disorders where systemic treatment may not adequately reach affected tissues.
Paediatric Rare-Disease Care
The sponsor’s clinical interest extends to children living with severe early-onset metabolic disease, with attention to safety, tolerability, and immune response in a paediatric population.
- Paediatric patients
- Safety and tolerability
- Immune response
This places the research within the field of rare disease neurology and paediatric translational medicine.
